By Josh White
Date: Wednesday 06 Oct 2021
(Sharecast News) - Massachusetts-based gene therapy company Voyager Therapeutics announced an agreement through which Pfizer could licence novel capsids generated from Voyager's RNA-driven 'TRACER', or 'Tropism Redirection of AAV by Cell-type-specific Expression of RNA' screening technology on Wednesday.
No recent information was found.
Currency | US Dollars |
Share Price | $ 3.36 |
Change Today | $ 0.01 |
% Change | 0.30 % |
52 Week High | $8.07 |
52 Week Low | $2.82 |
Volume | 433,002 |
Shares Issued | 36.83m |
Market Cap | $123.75m |
Beta | 0.77 |
RiskGrade | 294 |
Strong Buy | 7 |
Buy | 5 |
Neutral | 0 |
Sell | 0 |
Strong Sell | 0 |
Total | 12 |
Time | Volume / Share Price |
16:00 | 24,192 @ $3.36 |
15:59 | 100 @ $3.36 |
15:59 | 100 @ $3.36 |
15:59 | 100 @ $3.36 |
15:59 | 100 @ $3.37 |
You are here: research